Medicenna Therapeutics Corp.

What they do

Medicenna is a clinical-stage immunotherapy company focused on engineering and developing 'Superkines'—enhanced versions of cytokines—to treat cancer. Its lead product candidate is MDNA11, a 'beta-enhanced' IL-2 Superkine designed to selectively activate cancer-killing immune cells. The company is headquartered in Toronto, Canada, and its common shares are listed on Nasdaq under the ticker MDNA. As of fiscal year ended March 31, 2023, it reported 69,637,469 common shares outstanding.

Revenue drivers

• MDNA11 (clinical-stage) — The lead product candidate, a beta-enhanced IL-2 Superkine, is in clinical development; no revenue is generated from product sales currently. Potential future revenue would come from licensing or commercialization.
• Other preclinical programs — The pipeline includes other Superkine candidates, but they are in early stages and not generating revenue.

Recent performance

For the fiscal year ended March 31, 2023, the company reported a net loss of US$16.8 million (or C$22.8 million), compared to a net loss of US$17.7 million (C$22.2 million) in the prior year. Research and development expenses were US$15.4 million (C$20.9 million), slightly down from US$16.1 million (C$20.2 million) in fiscal 2022. General and administrative expenses decreased to US$6.3 million (C$8.6 million) from US$7.7 million (C$9.7 million). As of March 31, 2023, cash and cash equivalents were US$38.4 million (C$52.2 million).

Strategy

Management is advancing MDNA11 through clinical trials, with a focus on establishing proof-of-concept in multiple solid tumor indications. The company is also developing its earlier-stage Superkine pipeline, including MDNA113, and leverages its proprietary platforms (e.g., IL-2 and IL-4/13) to create differentiated candidates. It aims to secure partnerships or licensing deals to support development and commercialization of its assets.

Risks

• Clinical development risk — MDNA11 is in early-stage trials; failure to show safety or efficacy could halt development.
• Financing risk — As a clinical-stage company with no approved products, it depends on equity offerings or partnerships to fund ongoing operations, and dilution risk is inherent.
• Regulatory risk — The company may face delays or rejections in obtaining approvals to conduct or advance clinical trials.
• Competition risk — There are many other companies developing IL-2-based and cytokine therapies for cancer, which could limit commercial prospects.

Outlook

Management expects to report clinical data from the ongoing MDNA11 Phase 1/2 trial (ABBIT) in fiscal 2024. It anticipates continued investment in R&D and possibly additional capital raises to extend its cash runway. The company is guiding toward advancing MDNA11 into later-stage studies if early results are positive.